Schnider children's medical center
Petah Tikva, 49202, Israel
NCT Number: NCT03574558
The "MD-Logic Switch Advisor" is a software product that is designed to assist in insulin dosage decision making and has two components:
A. MD-Logic Switch Advisor for initiation of pump therapy - this product is designed to assist physicians in decision making when initiating insulin pump therapy.
B. MD-Logic Switch Advisor for patients who use insulin pump therapy and need to switch to MDI (Multiple Daily Injections).
This feasibility study will be divided to two parts:
part A - will include up to 20 patients to evaluate in a feasibility study the switch Advisor from MDI to pump therapy part B - will include up to 20 patients to evaluate in a feasibility study the switch Advisor from pump therapy to MDI The main objective is to evaluate the safety and efficacy of using the MD-Logic Switch Advisor to determine insulin dosing for subjects with type 1 diabetes using pump therapy who wish to switch to from pump to MDI therapy and vice versa.
Looking for future studies?
Notify Me6 year–30 year
All sexes
Interventional
Not applicable
Petah Tikva, 49202, Israel
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Study algorithm will be used in order to determine the initial pump setting/ MDI dosing while switching from from MDI to pump therapy or vice versa
Time frame: Day 14
Looking for future studies?
Notify MeRabin Medical Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06753994
Behavior, Diabetes
Montreal, Quebec, Canada
View Trial DetailsNCT05933018
Autoimmune Diseases, Diabetes Mellitus
Afula, Israel/Zaphon, Israel
View Trial DetailsNCT03761186
Autoimmune Diseases, Diabetes Mellitus
Stockholm, Sweden
View Trial DetailsNCT05557227
Glucose Metabolism Disorders, Hyperglycemia
Aarhus, Region Midt, Denmark
View Trial Details